Ondine Biomedical Inc.

AIM:OBI Stock Report

Market Cap: UK£34.5m

Ondine Biomedical Valuation

Is OBI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OBI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OBI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OBI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OBI?

Key metric: As OBI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for OBI. This is calculated by dividing OBI's market cap by their current revenue.
What is OBI's PS Ratio?
PS Ratio38.1x
SalesCA$1.63m
Market CapCA$62.27m

Price to Sales Ratio vs Peers

How does OBI's PS Ratio compare to its peers?

The above table shows the PS ratio for OBI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.8x
AGL ANGLE
15.3x51.5%UK£31.0m
BELL Belluscura
10.8x151.8%UK£15.6m
CREO Creo Medical Group
2.5x-4.9%UK£76.4m
POLX Polarean Imaging
10.5x49.6%UK£15.7m
OBI Ondine Biomedical
38.1x66.0%UK£34.5m

Price-To-Sales vs Peers: OBI is expensive based on its Price-To-Sales Ratio (38.1x) compared to the peer average (9.8x).

Price to Sales Ratio vs Industry

How does OBI's PS Ratio compare vs other companies in the GB Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
SPEC INSPECS Group
0.2x4.0%US$58.70m
YGEN Yourgene Health
0.6xn/aUS$20.48m
IHC Inspiration Healthcare Group
0.3x13.6%US$14.07m
SUN Surgical Innovations Group
0.4xn/aUS$6.44m
No more companies available in this PS range
OBI 38.1xIndustry Avg. 2.6xNo. of Companies4PS02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: OBI is expensive based on its Price-To-Sales Ratio (38.1x) compared to the UK Medical Equipment industry average (2.6x).

Price to Sales Ratio vs Fair Ratio

What is OBI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OBI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio38.1x
Fair PS Ratio15.5x

Price-To-Sales vs Fair Ratio: OBI is expensive based on its Price-To-Sales Ratio (38.1x) compared to the estimated Fair Price-To-Sales Ratio (15.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OBI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£0.085
UK£0.60
+605.9%
8.3%UK£0.65UK£0.55n/a2
Dec ’25UK£0.077
UK£0.60
+674.2%
8.3%UK£0.65UK£0.55n/a2
Nov ’25UK£0.087
UK£0.57
+557.1%
13.0%UK£0.65UK£0.50n/a2
Oct ’25UK£0.068
UK£0.55
+714.8%
18.2%UK£0.65UK£0.45n/a2
Sep ’25UK£0.07
UK£0.55
+685.7%
18.2%UK£0.65UK£0.45n/a2
Aug ’25UK£0.083
UK£0.55
+566.7%
18.2%UK£0.65UK£0.45n/a2
Jul ’25UK£0.077
UK£0.55
+609.7%
18.2%UK£0.65UK£0.45n/a2
Jun ’25UK£0.07
UK£0.55
+685.7%
18.2%UK£0.65UK£0.45n/a2
May ’25UK£0.051
UK£0.55
+973.2%
18.2%UK£0.65UK£0.45n/a2
Apr ’25UK£0.092
UK£0.57
+521.6%
13.0%UK£0.65UK£0.50n/a2
Jan ’25UK£0.087
UK£0.57
+557.1%
13.0%UK£0.65UK£0.50n/a2
Dec ’24UK£0.088
UK£0.57
+549.7%
13.0%UK£0.65UK£0.50UK£0.0772
Nov ’24UK£0.12
UK£0.57
+400.0%
13.0%UK£0.65UK£0.50UK£0.0872
Oct ’24UK£0.092
UK£0.57
+521.6%
13.0%UK£0.65UK£0.50UK£0.0682
Sep ’24UK£0.095
UK£0.57
+505.3%
13.0%UK£0.65UK£0.50UK£0.072
Aug ’24UK£0.16
UK£0.57
+259.4%
13.0%UK£0.65UK£0.50UK£0.0832
Jul ’24UK£0.13
UK£0.57
+360.0%
13.0%UK£0.65UK£0.50UK£0.0772
Jun ’24UK£0.15
UK£0.57
+271.0%
13.0%UK£0.65UK£0.50UK£0.072
May ’24UK£0.19
UK£0.63
+228.9%
4.0%UK£0.65UK£0.60UK£0.0512
Apr ’24UK£0.16
UK£0.63
+296.8%
4.0%UK£0.65UK£0.60UK£0.0922
Mar ’24UK£0.17
UK£0.95
+458.8%
48.4%UK£1.60UK£0.60UK£0.0983
Feb ’24UK£0.20
UK£0.95
+375.0%
48.4%UK£1.60UK£0.60UK£0.103
Jan ’24UK£0.20
UK£0.95
+363.4%
48.4%UK£1.60UK£0.60UK£0.0873
Dec ’23UK£0.24
UK£0.95
+287.8%
48.4%UK£1.60UK£0.60UK£0.0883

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 08:59
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ondine Biomedical Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew SimmsArden Partners Plc.
David DeanCormark Securities Inc.
Charles WestonRBC Capital Markets